Rosuvastatin
DrugOther names: Crestor
NCT Number: NCT00654225
The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in South Asian subjects with hypercholesterolemia.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Crestor
Other names: Lipitor
Time frame: 6 weeks
Time frame: 6 weeks
AstraZeneca
Industry
A 6-Week, Randomized,Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in South Asian Subjects.
Acronym: IRIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00653744
Dyslipidaemia, Dyslipidemias
View Trial DetailsNCT00653965
Dyslipidaemia, Dyslipidemias
View Trial DetailsNCT07655960
Dyslipidemia, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT05988866
Dyslipidemias, Hypercholesterolemia
Hamburg, Germany
View Trial Details